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Abstract
Background
Saphenous vein graft (SVG) may occlude either early or several months to years after coronary artery bypass
graft (CABG) surgery. Doing re-do CABG surgery is associated with higher complication and mortality rate as
compared to percutaneous coronary intervention (PCI) in SVG. However, PCI of SVG is associated with more
periprocedural and in-hospital complications as compared to PCI of native coronary arteries. Due to the
scarcity of local data in this regard, this study was designed to estimate the periprocedural and in-hospital
outcomes among PCI in SVG.
Objectives
We aim to study the periprocedural and in-hospital outcomes among patients who underwent PCI in SVG.
Methods
It is a retrospective observational study. We reviewed hospital record files of 167 consecutive patients,
admitted to Aga Khan University Hospital, Karachi, from January 2010 to December 2019, who underwent
PCI in SVG.
Results
Out of 167 patients, 145 (86.8%) were male with a mean age of 72.26 (±8.46) years. Hypertension was the
most common comorbid condition. Majority of 141(84.4%) patients presented within 6-10 years since the
last CABG done. Seventy-eight (46.7%) patients presented with non-ST elevation myocardial infarction
(NSTEMI). Patients who presented with acute coronary syndrome (ACS), 51 (36.9%), and 21 (15.2%) had
congestive heart failure and cardiogenic shock on presentation respectively. Coronary angiography was
performed in the majority of 155 (92.8%) patients through the femoral artery. The body of the SVG was the
most common site affected by the disease. In 88 (52.7%) patients stents were deployed in SVG to obtuse
marginal (OM). Drug-eluting stents (DES) were used in 124 (74.3%) patients. 22 (13.2%) of patients
developed periprocedural complications, predominantly slow flow and 7 (4.2)% patients had in-hospital
complications.
Conclusions
PCI of SVG is associated with a high procedural success rate and acceptable risk for periprocedural and in-
hospital complications. PCI of SVG may be considered as a safe and efficacious option for the percutaneous
intervention of SVG lesions.
Categories: Cardiology
Keywords: saphenous vein graft, percutaneous coronary intervention, coronary artery bypass graft surgery, acute
coronary syndrome, chronic stable angina
Introduction
Coronary artery disease (CAD) is one of the leading causes of death in South East Asia and the rest of the
world [1]. Besides risk factors modification and optimal medical therapy, revascularization (percutaneous
coronary intervention [PCI] and coronary artery bypass graft [CABG]) is one of the main streamlined part of
the management protocol in patients with CAD [2].
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saphenous vein graft (SVG) may occur either early or after several months or years after CABG. Occlusion of
graft is usually caused by graft failure or a combination of graft failure and progression of coronary
atherosclerosis. The type of lesion responsible for graft occlusion depends on the time of onset of ischemic
symptoms. Ischemia in acute graft occlusion is mostly due to surgical problems. Late graft occlusion is
usually caused by disease progression, graft degeneration and new atherosclerosis [4].
Approximately 10% of SVGs are occluded early postoperatively, 20% at one year and 50% at 10 years of
follow-up. Furthermore, 70% of SVGs were found to be diffusely diseased at 10 years [5]. The mode of
intervention in patients presenting with graft occlusion remains a subject of debate. Doing re-do CABG
surgery has higher complication rates and mortality as compared to PCI in SVG [6]. Re-do CABG is related to
higher morbidity and mortality rates moreover as poorer outcomes as compared to initial CABG surgery [7].
PCI of SVG has a better outcome as compared to re-do CABG. But PCI of SVG is related to additional
periprocedural and in-hospital complications as compared to PCI of native coronary arteries [8]. Due to
scarcity of local data in this regard, this study was designed to estimate the periprocedural (dissection,
perforation, slow flow/no flow, procedural failure and emergency CABG) and in-hospital outcomes (target




It is a retrospective observational study done at Aga Khan University Hospital, Karachi, which is a
multidisciplinary tertiary care hospital with a cardiology and cardiac surgery center and it is one of the main
referral health facilities in Pakistan. This study was approved by ethical review committee. We reviewed
hospital record files of consecutive 167 patients, admitted from January 2010 to December 2019, who
underwent PCI in SVG.
For all patients, demographic information including age and gender, mode of presentation, cardiogenic
shock status, and congestive heart failure were recorded after reviewing written medical records.
Comorbidities were tabulated including Diabetes mellitus (DM), hypertension, prior CAD, prior PCI, chronic
kidney disease (CKD), chronic obstructive pulmonary disease (COPD), smoking, peripheral arterial disease,
cerebrovascular disease, ejection fraction (EF), and years since last CABG done.
Procedure
Before the procedure, all patients were loaded with oral aspirin (300 mg) and clopidogrel (300-600 mg). After
informed consent for procedure, coronary angiography was performed by an interventional or non-
interventional cardiologist. The vascular access site was the discretion of the primary operator. During the
procedure, all patients received intravenous un-fractionated heparin according to body weight. Details of
coronary angiography including vascular access site, graft anastomosed to the coronary artery, location of
the lesion in SVG were recorded.
PCI in SVG was performed by an interventional cardiologist. The use of antiplatelet glycoprotein (GP)
IIb/IIIa inhibitor and type of stent {DES or bare-metal stent (BMS)} was at the discretion of the operator.
Details of PCI in SVG including stent characteristics (number, type, and size), direct stenting, thrombus
aspiration, pre-dilation, post-dilation, size of balloon used for post-dilation, use of intravascular ultrasound
(IVUS), fractional flow reserve (FFR), and GP IIb/IIIa inhibitor were recorded. Periprocedural outcomes
related to PCI in SVG including dissection, perforation, slow flow/no flow, procedural failure, and emergency
CABG were recorded.
All patients were followed from the time of the procedure to the time of discharge or death. Patients were
observed during the hospital stay for PCI-related in-hospital complications including major bleeding,
hematoma needed a blood transfusion, TLR, and in-hospital death.
Procedural success was defined as the achievement of residual in-stent stenosis of less than 30%, associated
with thrombolysis in myocardial infarction (TIMI) flow grade 3, in the absence of a dissection more than D1
and perforation without the occurrence of death or repeat TLR during the index hospital stay [9]. All deaths
were considered to be cardiac unless an unequivocal non-cardiac cause could be established [10]. TLR was
defined as repeat PCI or CABG performed because of restenosis of the target lesion in association with
angina or objective evidence of myocardial ischemia [11]. Major bleeding is defined as patients with
intracranial hemorrhage or a ≥5 g/dl decrease in hemoglobin concentration or a ≥15 % absolute decrease in
hematocrit [12].
Statistical analysis
To describe the characteristics of the study population we reported frequencies and proportions for the
categorical variables such as gender, diabetes or hypertension, etc. We checked the normality assumption for
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continuous variables by histograms superimposed with the normal curve. We reported mean and standard
deviation for normally distributed continuous variables (age), otherwise, we reported median and
interquartile range (IQR) if data were skewed. We used a Chi-squared test or Fisher’s exact to assess the
frequency distribution and the relationship between co-variates and periprocedural and in-hospital
complications for categorical variables. We considered a p-value of less than 0.05 for significant results. All




Overall, we analyzed data for 167 admitted patients. The mean age of the patients was 72.26 years with an
SD of 8.46. We found that more than three-fourths of the patients 145 (86.6%) were males. Moreover, 113
(67.7%) of the patients were diabetic and 153 (91.6%) were hypertensive (Table 1). Around three-fourth 138
(82.6%) of the patients had dyslipidemia and 36 (21.6%) were found to be smokers. We did not find a high
prevalence of COPD in the study participants, however, around one fourth 40 (24%) of patients were
suffering from CKD, 120 (71.9%) of the patients had a history of prior MI, 59 (35.3%) had a history of prior
PCI, 6 (3.6%) reported having peripheral arterial disease, and 13 (7.8%) of the patients had cerebrovascular
disease. The duration since last CABG was 6 to 10 years for more than three-fourths 141 (84.4%) of the
patients (Table 1).
Variables n (%)
Age, mean (SD) year 72.26 (8.46)
Male 145 (86.8)
Diabetes mellitus 113 (67.7)
Hypertension 153 (91.6)
Dyslipidemia 138 (82.6)
Smoking status 36 (21.6)
COPD 4 (2.4)
CKD 40 (24)
Prior MI 120 (71.9)
Prior PCI 59 (35.3)
Peripheral arterial disease 6 (3.6)
Cerebrovascular disease 13 (7.8)
Years since last CABG done  
   0-1 3 (1.8)
   2-5 23 (13.8)
   6-10 141 (84.4)
TABLE 1: Patients demographics and baseline characteristics (n = 167).
MI: myocardial infarction; CVA: cerebrovascular accident; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; SD:
standard deviation; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease.
Mode of presentation and hemodynamic status 
Majority of patients, presented with NSTEMI 78 (46.7%) followed by unstable angina 36 (21.6%). Only 24
(14.4%) patients presented with STEMI and 29 (17.4%) patients presented with chronic stable angina (CSA).
Of patients who presented with ACS, 51 (36.9%) had congestive heart failure and 21 (15.2%) had a
cardiogenic shock on presentation. The median EF of the patients was 45% with an IQR of 20 (Table 2).
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Variables n (%)
Mode of presentation  
  Chronic stable angina 29 (17.4)
  Unstable angina 36 (21.6)
  NSTEMI 78 (46.7)
  STEMI 24 (14.4)
Congestive heart failure 51 (36.9)
Cardiogenic shock 21 (15.2)
EF% (median- IQR) 45 (20)
TABLE 2: Mode of presentation and hemodynamic status.
NSTEMI: non-ST elevation myocardial infarction; STEMI: ST-elevation myocardial infarction; EF: ejection fraction; IQR: interquartile range.
Vascular access and coronary angiography characteristics
Coronary angiography was performed in the majority of 155 (92.8%) patients through the femoral artery
followed by left radial artery 8 (4.8%), and only in 4 (2.4%) patients, was performed through the right radial
artery. In 79% of patients, LIMA was anastomosed to the left anterior descending artery (LAD). The
anastomosis of SVG to OM, LAD, RCA, PDA, Ramus, and Diagonal was found in 152(91%), 35(21%),
77(46.1%), 65 (38.9%), and 20 (12%), 17 (10.2%) respectively. Only in 5 (3%) and 1 (0.6%) patients, RIMA and
radial artery were anastomosed with coronary arteries respectively. Coronary angiography revealed the site
of lesion in SVG, 105(62.9%) of the patients had a lesion in the body of SVG, 41 (24.6%) had lesion at the
aortic anastomosis and 21 (12.6%) had lesion at the distal anastomosis (Table 3).
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Variables n (%)
Vascular access  
  Femoral artery 155 (92.8)
  Left radial 8 (4.8)
  Right radial 4 (2.4)
Graft anastomosed to  
  LIMA to LAD 132 (79)
  SVG to LAD 35 (21)
  SVG to diagonal 17 (10.2)
  SVG to ramus 20 (12)
  SVG to OM 152 (91)
  SVG to RCA 77 (46.1)
  SVG to PDA 65 (38.9)
  Radial 1 (0.6)
  RIMA 5 (3)
  LIMA to diagonal 4 (2.4)
SVG lesion location  
  Aortic anastomosis 41 (24.6)
  Body 105 (62.9)
  Distal anastomosis 21 (12.6)
TABLE 3: Coronary angiography characteristics.
SVG: saphenous vein graft; LAD: left anterior descending artery; OM: obtuse marginal; RCA: right coronary artery; PDA: posterior descending artery;
LIMA: left internal mammary artery; RIMA: right internal mammary artery.
PCI of SVG characteristics
The majority of stents were deployed in SVG to OM 88 (52.7%) followed by RCA 26 (15.6%). Ten (6%)
patients had PCI of two grafts. Thrombus aspiration was performed in 45 (26.9%) of patients due to the high
burden of thrombus. GP IIb/IIIa inhibitor was used in 65 (38.9%) patients. The lesion was pre-dilated in 103
(61.7%) of patients, while in 64 (38.3%) patients stents were directly deployed. DES was used in 124 (74.3%)
patients, while BMS was the second most common which was used in 37 (22.2%) of patients, and in 6 (3.5%)
patients only drug-eluting balloon (DEB) angioplasty was performed. In 112(67.1%) of patients only one
stent was used and in 55 (32.9%) patients two or more stents were used. The stents used had a mean length
and range of 31.24/8-144 mm. Post dilation was done in 124 (74.3%) patients with a mean balloon size of
3.36 mm and with a minimum to a maximum size of 2.0-6.0 mm. IVUS was performed before and after stent
deployment in 12 (7.2%) patients (Table 4).
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Variables n (%)
Saphenous vein graft stented  
  SVG to LAD 12 (7.2)
  SVG to Diagonal 17 (10.2)
  SVG to Ramus 2 (1.2)
  SVG to OM 88 (52.7)
  SVG to RCA 26 (15.6)
  SVG to PDA 22 (13.2)
Number of stents deployed in patients  
  One 112 (67.1)
  Two or more 55 (32.9)
Type of stents  
  DES 124 (74.3)
  BMS 37 (22.2)
  POBA/DEB 6 (3.5)
Stent diameter (median- IQR) 3.5 (3)
Stent length mean with min-max (mm) 31.24/8-144
Direct stenting 64 (38.3%)
Pre-dilation 103  (61.7%)
Post-dilation 124(74.3%)
Thrombus aspiration 45 (26.9%)
Balloon size for post dilation mean/min-max (mm) 3.36/2.0-6.0
IVUS used 12 (7.2%)
GP IIb/IIIa inhibitor use 65 (38.9%)
TABLE 4: PCI of SVG characteristics.
DES: drug-eluting stent; BMS: bare-metal stent; DEB: drug-eluting balloon; POBA: plane old balloon angioplasty; IVUS: intravascular ultrasound;
GP: glycoprotein; LAD: left anterior descending artery; OM: obtuse marginal; RCA: right coronary artery; PDA: posterior descending artery; IQR:
interquartile range: PCI: percutaneous coronary intervention; SVG: saphenous vein graft.
Incidence of periprocedural and in-hospital complications
One of the main objectives of the study was to measure the incidence of overall periprocedural and in-
hospital complications. The findings of the study illustrated that the incidence of periprocedural
complications among the study population was 22 (13.2%), while the incidence of in-hospital complications
was relatively lower 7 (4.2%) as shown in Table 5. Within periprocedural complications, the most common
complication was slow flow with an incidence of 13 (7.8%) followed by dissection 8 (4.8%), and procedural
failure 1 (0.6%) as shown in Table 5. Likewise, the most common type of in-hospital complication was
mortality 4 (2.4%) followed by hematoma 3(1.8%) as shown in Table 5.
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Periprocedural complications n % In-hospital complications n %
Overall periprocedural complications 22 13.2 Overall in-hospital complications  7 4.2
Dissection 8 4.8 Major bleeding 0 0
Perforation 0 0 Hematoma 3 1.8
Slow flow 13 7.8 TLR 0 0
Emergency CABG 0 0 Death 4 2.4
Procedural failure 1 0.6    
TABLE 5: Incidence of different types of periprocedural and in-hospital complications (n = 167).
TLR: target lesion revascularization; CABG: coronary artery bypass graft.
Characteristics of patients by type of complications
We found that 50% of the patients with periprocedural complications were older than 70 years when
compared with 62.8% of the patients without periprocedural complications. Similarly, 63.6% of the patients
with periprocedural complications and 68.3% of their counterparts were diabetic (p-value: 0.63). A
significantly higher proportion of patients without periprocedural complications (93.8%) were hypertensive
compared to patients with periprocedural complications (77.3%; p-value: 0.009). About one-third of the
patients with periprocedural complications (31.8%) were smokers when compared to 20.0% of patients
without periprocedural complications (p-value: 0.21) as shown in Table 6. Around 4.5% of the patients with
periprocedural complications had CKD as opposed to 26.9% of the patients without periprocedural
complications (p-value: 0.02). Around 9% of the patients with periprocedural complications had CSA when
compared to 18.6% of patients without periprocedural complications. We did not find any significant
differences between patients with and without periprocedural complications on factors such as gender,
dyslipidemia, prior MI, cerebrovascular disease, and prior PCI as shown in Table 6.
 Periprocedural complications  In-hospital complications  
 No Yes p-value No Yes p-value*
 n % n %  n % n %  
Age (years)
  ≤ 70 54 37.2 11 50
0.25
63 39.4 2 28.6
0.70
  >70 91 62.8 11 50 97 60.6 5 71.4
Gender
  Male 126 86.9 19 86.4
0.94
140 87.5 5 71.4
0.23
  Female 19 13.1 3 13.6 20 12.5 2 28.6
DM
  No 46 31.7 8 36.4
0.63
51 31.9 3 42.9
0.41
  Yes 99 68.3 14 63.6 109 68.1 4 57.1
Hypertension
  No 9 6.2 5 22.7
0.009
13 8.1 1 14.3
0.46
  Yes 136 93.8 17 77.3 147 91.9 6 85.7
Dyslipidemia
  No 26 17.9 3 13.6
0.77
29 18.1 0 0
0.25
  Yes 119 82.1 19 86.4 131 81.9 7 100
Smoking status
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  No 116 80 15 68.2
0.21
126 78.8 5 71.4
0.47
  Yes 29 20 7 31.8 34 21.3 2 28.6
COPD
  No 142 97.9 21 95.5
0.43
157 98.1 6 85.7
0.16
  Yes 3 2.1 1 4.5 3 1.9 1 14.3
CKD
  No 106 73.1 21 95.5
0.02
125 78.1 2 28.6
0.009
  Yes 39 26.9 1 4.5 35 21.9 5 71.4
Prior MI
  No 43 29.7 4 18.2
0.32
46 28.7 1 14.3
0.36
  Yes 102 70.3 18 81.8 114 71.3 6 85.7
Prior PCI
  No 4 64.8 14 63.6
0.91
102 63.7 6 85.7
0.22
  Yes 51 35.2 8 36.4 58 36.3 1 14.3
PAD
  No 139 95.9 22 100
1
155 96.9 6 85.7
0.23
  Yes 6 4.1 0 0 5 3.1 1 14.3
CVA
  No 134 92.4 20 90.9
0.68
148 92.5 6 85.7
0.44
  Yes 11 7.6 2 9.1 12 7.5 1 14.3
Years since CABG
  0-1 year 3 2.1 0 0
0.66
3 1.9 0 0
0.93  2-5 years 19 13.1 4 18.2 22 13.8 1 14.3
  6-10 years 123 84.8 18 81.8 135 84.4 6 85.7
Mode of presentation
  CSA 27 18.6 2 9.1
0.27
29 18.1 0 0
0.26
  ACS 118 81.4 20 90.9 131 81.9 7 100
TABLE 6: Demographic and clinical characteristics of patients by type of complications (n = 167).
DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; MI: myocardial infarction; PCI: percutaneous
coronary intervention; PAD: peripheral arterial disease; CVA: cerebrovascular disease; CABG: coronary artery bypass graft; CSA: chronic stable
angina; ACS: acute coronary syndrome.
Likewise, we explored differences in the sociodemographic and clinical characteristics by in-hospital
complications. The study findings revealed that 71.4 % of the patients with in-hospital complications were
older than 70 years when compared with 60.6% of the patients without in-hospital complications. Similarly,
57.1% of the patients with in-hospital complications and 68.1% of their counterparts were diabetic (p-value:
0.41). Further, 85.7% of patients with in-hospital complications were hypertensive compared to 91.9% of the
patients without in-hospital complications, however, unlike periprocedural complications the findings were
not significant for hypertension (p-value: 0.46). About more than a quarter of the patients with in-hospital
complications (28.6%) were smokers when compared to 21.3% of patients without in-hospital complications
(p-value: 0.21) as shown in Table 6. Around 71.4% of the patients with in-hospital complications had CKD as
opposed to 21.9% of the patients without in-hospital complications and findings were statistically
significant (p-value: 0.009). We did not find any significant differences between patients with and without
in-hospital complications on factors such as gender, dyslipidemia, prior MI, cerebrovascular disease, and
prior PCI as shown in Table 6.
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Discussion
To the best of our knowledge, this is the largest hospital-based study performed to date examining the
periprocedural and in-hospital outcomes in patients who underwent PCI in SVG from Pakistan. In our study
population majority of patients presented with ACS, predominantly NSTEMI. More than 80% of our study
population presented within 6-10 years since the last CABG was done. This study shows that SVG to OM is
the most common graft and the body of the graft is the most common site of the lesion, which required
intervention and the DES is the most common stent deployed in the SVG. In our study, population procedure
success is very high however, 22 (13.2%) of patients developed periprocedural complications with
predominantly slow flow and 7 (5%) of patients had in-hospital complications among which 4(2.4%) patients
died during hospital stay.
ACS, predominantly NSTEMI was the most common presentation in our study population who required PCI
in SVG and this finding is consistent with the study of Brilakis et al, in their study most of the patients
presented with the ACS, predominantly NSTEMI for intervention in SVG [13].
In our study population, more than 80% of patients presented within 6-10 years of since last CABG done with
graft failure. This finding is consistent with the Fitzgibbon GM et al study. In their study population, more
than 50% of patients presented with graft failure within 10 years since the last CABG was done [5].
DES was the most commonly used in our study population this finding is consistent with the
literature. Brilakis et al. and Mehilli et al. used DES in most of their study population [14,15]. Mosleh et al.
and Ybarra et al. also used DES in most of their study population and it showed lesser adverse cardiac event
as compared to BMS [16,17].
In our study population, the periprocedural complication was observed in 22 (13.4%) of patients with
predominantly low flow in 13 (7.8%) of patients. In our study population, they developed slow flow in a
lesser number as compared to Shakoor et al and Sharma et al. study populations. Shakoor et al. reported a
slow flow of 11.5% [18] and Sharma et al. as high as 18% in their study population who underwent PCI in
SVG [19].
There was only 4 (2.4%) mortality in our study population. All four patients died due to primarily underlying
cardiovascular etiology. It is consistent with the results of the study conducted by Brilakis et al. and their
study reported 5% mortality in their study population [20].
Our study is not free of limitations. It is a retrospective observational study, conducted in a single center
and the sample size is small which may not represent the whole Pakistani population. There is no control
group, so it is not possible to establish the association of PCI in SVG with mortality. There is no long-term
follow-up. We suggest prospective randomized studies to predict the long-term outcomes of PCI in SVG in
our region.
Conclusions
PCI and CABG are complementary treatment modalities in patients with CAD. PCI in SVG lesions appears
reasonable and safe with a decent periprocedural and in-hospital outcomes. Improvements in the expertise
of interventionists and efficacy of antiplatelet, anticoagulation, and devices are expected to helper in more
favorable outcomes for PCI in SVG.
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